Ortin Global Ltd has received a disclosure filing from Suresh Gadala and his persons acting in concert (PACs) following their acquisition of equity shares that pushed their combined shareholding above the 5% threshold, triggering mandatory regulatory disclosure requirements.

Acquisition Details

The acquisition involved the purchase of 31,640 equity shares on February 23, 2026, through open market transactions. This purchase increased the group's total shareholding from 3,99,421 shares to 4,31,061 shares in the company.

Acquirer Group Structure

The acquirer group consists of Suresh Gadala as the primary acquirer along with two persons acting in concert:

• Kamal Gadalay (Wife of Suresh Gadala)
• Aditya Gadalay (Son of Suresh Gadala)

The disclosure confirms that the acquirer group does not belong to the promoter or promoter group of Ortin Global Ltd.

Company Share Capital Structure

Ortin Global Ltd's equity share capital remains unchanged following this acquisition:

Regulatory Compliance

The disclosure was filed on February 25, 2026, in compliance with Regulation 29(1) & 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015. The filing was necessitated as the group's shareholding crossed the 5% threshold limit specified under the SAST Regulations.

The acquirer group holds no encumbrances, voting rights other than equity shares, or convertible securities in the company. All holdings are in the form of equity shares carrying voting rights.

Ortin Global Limited has received a detailed public statement from Mr. Parveen Satija announcing an open offer to acquire a significant stake in the pharmaceutical and chemicals company. The announcement, made through manager Rarever Financial Advisors Private Limited, outlines the acquirer's intention to purchase 21,14,162 equity shares representing 26% of the company's voting capital.

Open Offer Details

The open offer presents a comprehensive acquisition proposal structured under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Mr. Parveen Satija, aged 55 years and residing in Delhi, has positioned himself to acquire control of the Target Company through this strategic transaction.

Background Transaction

The open offer stems from a Share Purchase Agreement executed on February 10, 2026, between the acquirer and four promoter sellers. This underlying transaction involves the acquisition of 1,00,300 equity shares representing 1.23% of the existing paid-up capital.

The aggregate consideration for the underlying Share Purchase Agreement amounts to ₹14,69,395, with all promoter sellers transferring their complete holdings to the acquirer.

Acquirer Profile and Financial Arrangements

Mr. Parveen Satija brings over 20 years of business experience and holds a Bachelor of Commerce degree from Punjab University, Chandigarh. He currently serves as Director of Samsung Electro Product Private Limited and has a certified net worth of ₹8.54 crores as of January 27, 2026.

The acquirer has established robust financial arrangements to support the open offer:

• Escrow Account: Opened with Axis Bank Limited under the name "PARVEEN SATIJA - OPEN OFFER ESCROW ACCOUNT"
• Escrow Deposit: ₹80,52,850 (more than 25% of total consideration)
• Funding Source: Internal resources without external borrowings
• Certification: Financial adequacy certified by M/s. Jay M. Shah & Co., Chartered Accountants

Offer Price Determination

The offer price of ₹14.65 per equity share has been determined in accordance with Regulations 8(1) and 8(2) of SEBI (SAST) Regulations, 2011. The price represents the highest among various parameters considered:

The equity shares of Ortin Global Limited are frequently traded on both BSE (Script Code: 539287) and NSE (Script Symbol: ORTINGLOBE), with annualized trading turnover of 50.67% on NSE and 19.63% on BSE during the twelve months prior to the public announcement.

Company Overview and Financial Performance

Ortin Global Limited, originally incorporated as Ortin Laboratories Private Limited in 1986, operates in the pharmaceutical and chemicals sector. The company manufactures and trades in various chemicals, medicines, food preparations, and healthcare products.

Recent financial performance shows:

Implementation Timeline

The open offer follows a structured timeline with key milestones:

• Public Announcement: February 10, 2026
• Detailed Public Statement: February 17, 2026
• Tendering Period: April 10, 2026 to April 24, 2026
• Payment Completion: By May 11, 2026
• Final Report Filing: May 18, 2026

BSE Limited serves as the designated stock exchange for tendering equity shares, with M/s. South Gujarat Shares & Sharebrokers Limited appointed as the buying broker. The offer will be implemented through the stock exchange's acquisition window mechanism.

Strategic Implications

Upon completion of the open offer, assuming full acceptance, Mr. Parveen Satija will hold 22,14,462 equity shares representing 27.23% of the paid-up equity share capital. The acquirer has stated intentions to expand business operations and drive the next phase of growth for the Target Company.

The transaction may result in the public shareholding falling below the minimum 25% requirement, necessitating steps to restore compliance with SEBI (LODR) Regulations within prescribed timelines. All existing promoter sellers will cease to be members of the promoter group following the completion of the underlying transaction.